Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

The rise and fall of Dimebon.

Bezprozvanny I.

Drug News Perspect. 2010 Oct;23(8):518-23. doi: 10.1358/dnp.2010.23.8.1500435.

2.

Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease.

Tebano MT, Martire A, Chiodi V, Ferrante A, Popoli P.

ScientificWorldJournal. 2010 Sep 1;10:1768-82. doi: 10.1100/tsw.2010.164. Review.

3.

Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments.

Gambazzi L, Gokce O, Seredenina T, Katsyuba E, Runne H, Markram H, Giugliano M, Luthi-Carter R.

J Pharmacol Exp Ther. 2010 Oct;335(1):13-22. doi: 10.1124/jpet.110.167551. Epub 2010 Jul 12.

4.

A novel peptide, colivelin, prevents alcohol-induced apoptosis in fetal brain of C57BL/6 mice: signaling pathway investigations.

Sari Y, Chiba T, Yamada M, Rebec GV, Aiso S.

Neuroscience. 2009 Dec 29;164(4):1653-64. doi: 10.1016/j.neuroscience.2009.09.049. Epub 2009 Sep 25.

5.

Brain-derived neurotrophic factor in neurodegenerative diseases.

Zuccato C, Cattaneo E.

Nat Rev Neurol. 2009 Jun;5(6):311-22. doi: 10.1038/nrneurol.2009.54. Review.

PMID:
19498435
6.

Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.

Estrada-Sánchez AM, Montiel T, Segovia J, Massieu L.

Neurobiol Dis. 2009 Apr;34(1):78-86. doi: 10.1016/j.nbd.2008.12.017. Epub 2009 Jan 9.

PMID:
19168136
7.

Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse.

Sari Y.

Neuroscience. 2009 Feb 18;158(4):1426-35. doi: 10.1016/j.neuroscience.2008.11.021. Epub 2008 Nov 21.

8.

Evaluation of Dimebon in cellular model of Huntington's disease.

Wu J, Li Q, Bezprozvanny I.

Mol Neurodegener. 2008 Oct 21;3:15. doi: 10.1186/1750-1326-3-15.

9.

Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications.

Brocklebank D, Gayán J, Andresen JM, Roberts SA, Young AB, Snodgrass SR, Penney JB, Ramos-Arroyo MA, Cha JJ, Rosas HD, Hersch SM, Feigin A, Cherny SS, Wexler NS, Housman DE, Cardon LR; International-Venezuela Collaborative Research Group..

Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):425-9. doi: 10.1002/ajmg.b.30826.

10.

Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV.

Neuroscience. 2008 Apr 22;153(1):329-37. doi: 10.1016/j.neuroscience.2008.02.004. Epub 2008 Feb 15.

11.

Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.

Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR.

J Neurosci. 2007 Oct 24;27(43):11758-68.

12.

Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease.

Cho SR, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA.

J Clin Invest. 2007 Oct;117(10):2889-902.

13.

Glutamate uptake is reduced in prefrontal cortex in Huntington's disease.

Hassel B, Tessler S, Faull RL, Emson PC.

Neurochem Res. 2008 Feb;33(2):232-7. Epub 2007 Aug 29.

PMID:
17726644
14.

Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease.

Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, Gall CM, Simmons DA.

J Neurosci. 2007 Apr 18;27(16):4424-34.

15.

Role of brain-derived neurotrophic factor in Huntington's disease.

Zuccato C, Cattaneo E.

Prog Neurobiol. 2007 Apr;81(5-6):294-330. Epub 2007 Feb 9. Review.

PMID:
17379385
16.

Activity-dependent neuroprotective protein: from gene to drug candidate.

Gozes I.

Pharmacol Ther. 2007 May;114(2):146-54. Epub 2007 Feb 1. Review.

PMID:
17363064
17.

IGF-I specifically enhances axon outgrowth of corticospinal motor neurons.

Ozdinler PH, Macklis JD.

Nat Neurosci. 2006 Nov;9(11):1371-81. Epub 2006 Oct 22.

PMID:
17057708
18.

Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis.

Matsuoka M, Hashimoto Y, Aiso S, Nishimoto I.

CNS Drug Rev. 2006 Summer;12(2):113-22. Review. Erratum in: CNS Drug Rev. 2007 Summer;13(2):278.

19.

Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.

Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I.

Neuron Glia Biol. 2004 Aug;1(3):193-9.

20.

Neuroprotective agents for clinical trials in ALS: a systematic assessment.

Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, Cudkowicz ME.

Neurology. 2006 Jul 11;67(1):20-7. Review.

PMID:
16832072

Supplemental Content

Support Center